HIMS · Hims & Hers Health, Inc.
$27.51
+0.26% last session
End-of-day data · close of 2026-09-11
Market cap
$6B
Enterprise value
$7B
Trailing P/E
—
Forward P/E
36.0
Dividend yield
—
Beta
2.41
Avg volume
15M
Employees
2K
Daily Change %
0.26%
5 Days Change
0.69%
10 Days Change
-5.68%
30 Days Change
-8.55%
60 Days Change
-18.85%
Month to Day Change
-1.90%
Year to Day Change
-14.07%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — HIMS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-24
Latest call per bank · past 12 months
Barclays
Overweight$35.00
+27.6% vs priceCitigroup
Neutral$33.00
+20.3% vs priceDeutsche Bank
Hold$26.00
-5.2% vs priceBank of America
Neutral$32.00
+16.6% vs priceMorgan Stanley
Equal-Weight$28.00
+2.0% vs priceJP Morgan
Overweight$33.00
+20.3% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-24 | Truist Securities | Maintains | Hold | $27.00 → $32.00 |
| 2026-08-21 | Barclays | Maintains | Overweight | $39.00 → $35.00 |
| 2026-08-11 | Citigroup | Maintains | Neutral | $35.00 → $33.00 |
| 2026-08-11 | Deutsche Bank | Maintains | Hold | $25.00 → $26.00 |
| 2026-08-11 | Bank of America | Maintains | Neutral | $30.00 → $32.00 |
| 2026-08-11 | TD Cowen | Maintains | Hold | $25.00 → $30.00 |
| 2026-08-11 | Morgan Stanley | Maintains | Equal-Weight | $21.00 → $28.00 |
| 2026-08-11 | Needham | Maintains | Buy | $35.00 → $42.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 43 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 11.4% below the 50-day MA ($31.04).
- Price vs 200-day MA: Trading 2.5% below the 200-day MA ($28.23).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.21) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($14.52) and high ($62.76).
HIMS Price Chart
Loading chart for HIMS…
Fundamentals
About Hims & Hers Health, Inc.
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$58B 16.8% YTD
TEVA
Teva Pharmaceutical Industries
$42B 18.1% YTD
HLN
Haleon plc
$41B -6.9% YTD
ZTS
Zoetis Inc.
$30B -40.8% YTD
UTHR
United Therapeutics Corporation
$22B 4.0% YTD
VTRS
Viatris Inc.
$19B 35.6% YTD
NBIX
Neurocrine Biosciences, Inc.
$16B 9.4% YTD
ELAN
Elanco Animal Health Incorporat
$11B 4.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.